The N3RO trial: A randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants <29 weeks' gestation

• Main Authors: Collins, C.T, Gibson, R.A, Makrides, M, McPhee, A.J, Sullivan, T.R, Davis, P.G, Thio, M, Simmer, K, Rajadurai, V.S, Ryan, P, Morris, S, Stark, M, Travadi, J, Wright, I, Tan, K, Holberton, J, Opie, G, Callander, I, Stack, J, Shein, D, Bellhouse, S, Bolisetty, S, Lui, K, Liley, H, Berry, M, Harris, D, Chua, M.C, Agarwal, P, The N3RO Investigative Te
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: 2020
• Subjects: docosahexaenoic acid; Article; child hospitalization; clinical protocol; controlled study; disease association; drug effect; drug efficacy; enteric feeding; female; gestational age; human; infant; lung dysplasia; major clinical study; male; multicenter study; newborn morbidity; outcome assessment; oxygen supply; prematurity; randomized controlled trial; treatment duration; clinical trial; dietary supplement; double blind procedure; emulsion; follow up; newborn; treatment outcome; Bronchopulmonary Dysplasia; Clinical Protocols; Dietary Supplements; Docosahexaenoic Acids; Double-Blind Method; Emulsions; Enteral Nutrition; Female; Follow-Up Studies; Humans; Infant, Newborn; Infant, Premature; Male; Treatment Outcome
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/181365
• Institution: National University of Singapore

10.1186/s12887-016-0611-0